Navigation Links
Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:9/18/2007

Technology Turns Off 'Master Switch' Underlying Bacterial Infection and May

Have Broad Use in Preventing Critical Bacterial Infections

BOSTON, Sept. 18 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. announced today the most advanced preclinical results of the Company's Multiple Adaptation Response (MAR) inhibitor program. MAR proteins in bacteria serve as the "master switch" controlling virulence and antibiotic resistance. Paratek has shown that shutting down this switch disables bacterial virulence and prevents bacteria from causing infection. Paratek is developing MAR inhibitors that can prevent serious and life-threatening bacterial infections in high-risk patients.

The results were reported in a "late breaker" poster presentation titled, "A Novel Anti-Virulence Approach for Treatment of Pneumonia Caused by Pseudomonas aeruginosa," at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Chicago. The findings demonstrated that small molecule agents which block the activity of ExsA (a MAR protein) in Pseudomonas aeruginosa significantly reduced bacterial virulence and were protective in an animal model from pneumonia. Lead authors on the research are Michael P. Draper, Ph.D., Director of Anti-Infective Drug Discovery at Paratek Pharmaceuticals, and Stuart B. Levy, M.D., Chief Scientific Officer and Co-Founder of Paratek.

In addition, Paratek announced a newly released publication showing efficacy of the Company's MAR inhibitors against E. coli in urinary tract infection in another animal model of serious bacterial infection. The article, titled, "Novel anti-infection agents: Small-molecule inhibitors of bacterial transcription factors," is appearing in the current August 2007 issue of Bioorganic & Medicinal Chemistry Letters.

Dr. Levy commented, "We are very pleased with the progress of the MAR program. We have shown proof of concept in E. coli, Yersinia and now Pseudomonas, a gram-n
'/>"/>

SOURCE Paratek Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
5. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
(Date:1/22/2015)... 22, 2015  Amgen (NASDAQ: AMGN ) today announced that ... results on Tuesday, Jan. 27, 2015, after the close of the ... call with the investment community at 2 p.m. PT. Participating in ... chairman and chief executive officer, and other members of Amgen,s senior ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/x3hp3g/microbiology ... "Microbiology Testing/Clinical Microbiology Market by Product, Clinical Application ... report to their offering. Clinical ... for the detection of infectious diseases. The respiratory ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3
... Reached in Key Lung Compartments, REINACH and ... Ltd. today announced promising,results of "first-in-man" studies ... a total of 19 healthy male,volunteers. , ... using Microdosing,for the determination of drug concentrations ...
... /PRNewswire-FirstCall/ -- ADVENTRX,Pharmaceuticals, Inc. , a ... commercializing proprietary product,candidates for the treatment ... that results from preclinical studies of ... (5-FU),and capecitabine (Xeloda(R)), an oral prodrug ...
Cached Medicine Technology:Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 2Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 3Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 4Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 5ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual,Meeting 2ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual,Meeting 3
(Date:1/22/2015)... Hollywood, California (PRWEB) January 22, 2015 The City ... 2015 at 10 a.m., to commemorate the 42nd anniversary of the ... United States. , “It’s been 42 years since the Roe vs. ... choose is still as present as ever,” said City of West ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method ... lean muscle by up to 30lbs in less than 12 ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... scientific diet formula that allows the body to pack on ...
(Date:1/22/2015)... 2015 Juvent Sports ( http://www.juventsports.com ) ... PGA Merchandise Show to bestow a Juvent Sports Achievement ... golfer, Arlene McKitrick. The award commemorated and congratulated McKitrick ... win. She won her first amateur tournament in 1979 ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Carinsurancesavings.biz has released ... accidental death and dismemberment insurance . , Purchasing an ... can be very advantageous. This type of rider provides benefits ... dismemberment can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... Palm City, Florida (PRWEB) January 22, 2015 ... use cold therapy machine with patented IsoTube design to treat ... has introduced the most progressive and easy to use ... help treat post-operative and sports related orthopedic and muscle injuries. ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... (HealthDay News) -- Women, but not men, with post-traumatic ... hormone, new research shows. The hormone -- pituitary ... central nervous system activity, metabolism, blood pressure, pain sensitivity ... in the Feb. 24 issue of Nature , ...
... HealthDay Reporter , WEDNESDAY, Feb. 23 (HealthDay ... pain -- an increasingly controversial treatment that has exploded ... to higher rates of permanent disability for worker,s compensation ... finds. Researchers randomly selected 725 people with low ...
... collaboration is bringing surgical patients closer to having ... trial, patients given neosaxitoxin, a new local anesthetic ... and recovered about two days sooner than those ... on this finding, Children,s Hospital Boston, a co-investigator ...
... of breast cancer survivors battle persistent fatigue, a Michigan ... a technique where physical pressure is applied to acupuncture ... can help alleviate symptoms. Gwen Wyatt will study ... two acupressure treatments on persistent cancer-related fatigue, a state ...
... - While studying one tumor-suppressing protein, Cheryl Walker,s research ... Center came across a separate surprise. They found another ... moonlighting out in the cell,s cytoplasm. Following up ... protein ATM has a second job controlling and killing ...
... San Francisco, CA February 22, 2011 The ... million in research grants as part of its Mobilizing ... populations with chronic diseases through the use of mobile-phone ... $250,000 each, will support studies on diabetes care and ...
Cached Medicine News:Health News:Spinal Fusion Surgery May Leave Some Back Pain Patients Worse Off: Study 2Health News:Spinal Fusion Surgery May Leave Some Back Pain Patients Worse Off: Study 3Health News:New long-acting local anesthetic derived from algae effectively blocks pain in surgical patients 2Health News:New long-acting local anesthetic derived from algae effectively blocks pain in surgical patients 3Health News:Acupressure shows promise in relieving fatigue in cancer survivors 2Health News:UT MD Anderson discovery wins 2010 Cozzarelli Prize 2Health News:McKesson Foundation awards $1.3 million in 6 Mobilizing for Health Research grants 2
... drainage from the ureteropelvic junction to ... packages. Intended for one-time use. CAUTION: ... Sof-Flex® stents must not remain indwelling ... stents must not remain indwelling more ...
... Pigtail Ureteral Stents have an exclusive ... migration. They also feature unique Tecoflex® ... savings. Each Classic Double PigTail Ureteral ... PigTail Ureteral Stent with attached braided ...
The Needle Loading Platform / Shield is designed to provide superior operator shielding during the loading of prostate implant needles with iodine or palladium seeds. It is constructed of 3/8" alumin...
The seed alignment tray aligns seeds and spacers for easy access to be picked up by the SeedVac™. It also interfaces with the seed sterilization and sorting tray for protection from radiation....
Medicine Products: